Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech, Inc. Message Board

  • bailey201306 bailey201306 Mar 8, 2014 11:05 AM Flag

    The Era of Immunotherapy has Arrived - see topic : "Immunotherapy: A New Approach using Oncolytic Viiruses"

    "Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy"

    Dmitriy Zamarin, Rikke B. Holmgaard, Sumit K. Subudhi, Joon Seok Park, Mena Mansour, Peter Palese, Taha Merghoub, Jedd D. Wolchokand James P. Allison

    Sci Transl Med 5 March 2014:
    Vol. 6, Issue 226, p. 226

    "Preexisting lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers. Recent studies also suggest that lymphocytic responses may identify patients more likely to benefit from therapies targeting immune checkpoints, suggesting that therapeutic efficacy of immune checkpoint blockade can be enhanced through strategies that induce tumor inflammation. "

    This work demonstrates that interest in virotherapy is becoming even more pronounced particularly as the number of clinical studies in this area increasingly demonstrate that virotherapy significantly contributes to immunotherapy. What has been clinically demonstrated is the ability of viruses to strip the cancers of their defensive immuno-protecitve shields and reveal the cancers to both the immune system and to other therapies such as the monoclonal antibodies - anti-PD1 and anti-PDL1, which result in CTLA-4 blockade (checkpoint blockade).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy"

      Dmitriy Zamarin, Rikke B. Holmgaard, Sumit K. Subudhi, Joon Seok Park, Mena Mansour, Peter Palese, Taha Merghoub, Jedd D. Wolchokand James P. Allison

      Sci Transl Med 5 March 2014:
      Vol. 6, Issue 226, p. 226

      "Preexisting lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers. Recent studies also suggest that lymphocytic responses may identify patients more likely to benefit from therapies targeting immune checkpoints, suggesting that therapeutic efficacy of immune checkpoint blockade can be enhanced through strategies that induce tumor inflammation. "

      This work demonstrates that interest in virotherapy is becoming even more pronounced particularly as the number of clinical studies in this area increasingly demonstrate that virotherapy significantly contributes to immunotherapy. What has been clinically demonstrated is the ability of viruses to strip the cancers of their defensive immuno-protecitve shields and reveal the cancers to both the immune system and to other therapies such as the monoclonal antibodies - anti-PD1 and anti-PDL1, which result in CTLA-4 blockade (checkpoint blockade

    • This why I have said to watch Amgen (& now Merck).

      Sentiment: Hold

    • Sure your did. Now you can bug off.

    • Researchers are showing that oncolytic virus infection alerts T-cells of the immune system to the presence of cancer cells, which otherwise suppress immune surveillance and attack. Subsequent injection of the anti-CTLA-4 antibody dials up the incipient anti-tumor response so dramaticallly that it overcomes the tumor's immune suprresion and destroys both virus-exposed tumors and any possible unexposed tumors. And the effect appears to be durable.

 
ONCY
0.33-0.02(-5.71%)Nov 4 4:00 PMEST